Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis

European Neuropsychopharmacology

Volumn 26, Issue 11, 2016, Pages 1752-1759

  de Vries, Ymkje Anna ^a   Roest, Annelieke M ^a   Beijers, Lian ^a   Turner, Erick H ^b,c   de Jonge, Peter ^a,d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Antidepressants; Anxiety; Bias; Depression; Harms

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DULOXETINE; FLUVOXAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADVERSE DRUG REACTION; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG SAFETY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GENERALIZED ANXIETY DISORDER; HOSTILITY; HUMAN; MAJOR DEPRESSION; MANIA; MENTAL INSTABILITY; META ANALYSIS; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; SOCIAL PHOBIA; SUICIDAL IDEATION; SYSTEMATIC ERROR; ANXIETY; COMPLICATION; DEPRESSION; STATISTICAL BIAS;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; BIAS; CLINICAL TRIALS AS TOPIC; DEPRESSION; HUMANS;

EID: 84994056981     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2016.09.370     Document Type: Article

References (50)

1. Andrisano, C., Chiesa, A., Serretti, A., Newer antidepressants and panic disorder: a meta-analysis. Int. Clin. Psychopharmacol. 28 (2013), 33–45.
2. Baldwin, D., Bobes, J., Stein, D.J., Scharwachter, I., Faure, M., Paroxetine in social phobia/social anxiety disorder: randomised, double- blind, placebo-controlled study. Br. J. Psychiatry 175 (1999), 120–126.
3. Bandelow, B., Reitt, M., Röver, C., Michaelis, S., Görlich, Y., Wedekind, D., Efficacy of treatments for anxiety disorders: a meta-analysis. Int. Clin. Psychopharmacol. 30 (2015), 183–192.
4. Blanco, C., Bragdon, L.B., Schneier, F.R., Liebowitz, M.R., The evidence-based pharmacotherapy of social anxiety disorder. Int. J. Neuropsychopharmacol. 16 (2013), 235–249.
5. Bradwejn, J., Ahokas, A., Stein, D.J., Salinas, E., Emilien, G., Whitaker, T., Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br. J. Psychiatry 187 (2005), 352–359.
6. Brady, K., Pearlstein, T., Asnis, G.M., Baker, D., Rothbaum, B., Sikes, C.R., Farfel, G.M., Efficacy and safety of sertraline treatment of posttraumatic stress disorder. J. Am. Med. Assoc., 283, 2000, 1837.
7. Chan, A.-W., Hróbjartsson, A., Haahr, M.T., Gøtzsche, P.C., Altman, D.G., Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. J. Am. Med. Assoc. 291 (2004), 2457–2465.
8. Dwan, K., Gamble, C., Williamson, P.R., Kirkham, J.J., Systematic review of the empirical evidence of study publication bias and outcome reporting bias – an updated review. PLoS One, 8, 2013, e66844.
9. Dwan, K., Altman, D.G., Clarke, M., Gamble, C., Higgins, J.P.T., Sterne, J.A.C., Williamson, P.R., Kirkham, J.J., Evidence for the selective reporting of analyses and discrepancies in clinical trials: a systematic review of cohort studies of clinical trials. PLoS Med, 11, 2014, e1001666.
10. Eyding, D., Lelgemann, M., Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ, 341, 2010, c4737.
11. Golden, R.N., Nemeroff, C.B., McSorley, P., Pitts, C.D., Dubé, E.M., Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J. Clin. Psychiatry 63 (2002), 577–584.
12. Hammad, T.A., Laughren, T.P., Racoosin, J., Suicidality in pediatric patients treated with antidepressant drugs. Arch. Gen. Psychiatry 63 (2006), 332–339.
13. Hartung, D., Zarin, D., Guise, J.-M., McDonagh, M., Paynter, R., Helfand, M., Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications. Ann. Intern. Med. 160 (2014), 477–483.
14. Healy, D., Herxheimer, A., Menkes, D.B., Antidepressants and violence: problems at the interface of medicine and law. PLoS Med., 3, 2006, e372.
15. Hidalgo, R.B., Tupler, L.A., Davidson, J.R.T., An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J. Psychopharmacol. 21 (2007), 864–872.
16. Hollander, E., Koran, L.M., Goodman, W.K., Greist, J.H., Ninan, P.T., Yang, H., Li, D., Barbato, L.M., A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J. Clin. Psychiatry 64 (2003), 640–647.
17. Hughes, S., Cohen, D., Jaggi, R., Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study. BMJ Open, 4, 2014, e005535.
18. Ioannidis, J.P.A., Lau, J., Completeness of safety reporting in randomized trials. J. Am. Med. Assoc., 285, 2001, 437.
19. Ioannidis, J.P.A., Evans, S., Gøtzsche, P.C., O'Neill, R.T., Altman, D.G., Schulz, K., Moher, D., Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann. Intern. Med. 141 (2004), 781–788.
20. Le Noury, J., Nardo, J.M., Healy, D., Jureidini, J., Raven, M., Tufanaru, C., Abi-Jaoude, E., Restoring study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ, 351, 2015, h4320.
21. Liebowitz, M.R., Mangano, R.M., Bradwejn, J., Asnis, G., A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J. Clin. Psychiatry 66 (2005), 238–247.
22. Liebowitz, M.R., Stein, M.B., Tancer, M., Carpenter, D., Oakes, R., Pitts, C.D., A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J. Clin. Psychiatry 63 (2002), 66–74.
23. Loke, Y.K., Derry, S., Reporting of adverse drug reactions in randomised controlled trials – a systematic survey. BMC Clin. Pharmacol., 1, 2001, 3.
24. Marshall, R.D., Beebe, K.L., Oldham, M., Zaninelli, R., Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am. J. Psychiatry 158 (2001), 1982–1988.
25. Maund, E., Tendal, B., Hróbjartsson, A., Jorgensen, K.J., Lundh, A., Schroll, J., Gøtzsche, P.C., Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. BMJ, 348, 2014, g3510.
26. Molero, Y., Lichtenstein, P., Zetterqvist, J., Gumpert, C.H., Fazel, S., Selective serotonin reuptake inhibitors and violent crime: a cohort study. PLoS Med., 12, 2015, e1001875.
27. Moore, T.J., Glenmullen, J., Furberg, C.D., Prescription drugs associated with reports of violence towards others. PLoS One, 5, 2010, e15337.
28. Olfson, M., Marcus, S.C., National patterns in antidepressant medication treatment. Arch. Gen. Psychiatry 66 (2009), 848–856.
29. Papanikolaou, P.N., Churchill, R., Wahlbeck, K., Ioannidis, J.P.A., Safety reporting in randomized trials of mental health interventions. Am. J. Psychiatry 161 (2004), 1692–1697.
30. Plint, A.C., Moher, D., Morrison, A., Schulz, K., Altman, D.G., Hill, C., Gaboury, I., Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med. J. Aust. 185 (2006), 263–267.
31. Pollack, M., Mangano, R., Entsuah, R., Tzanis, E., Simon, N.M., Zhang, Y., A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology 194 (2007), 233–242.
32. Rickels, K., Mangano, R., Khan, A., A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J. Clin. Psychopharmacol. 24 (2004), 488–496.
33. Riveros, C., Dechartres, A., Perrodeau, E., Haneef, R., Boutron, I., Ravaud, P., 2013. Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals K. Dickersin, ed. PLOS Med., 10, e1001566.
34. Roest, A.M., de Jonge, P., Williams, C.D., de Vries, Y.A., Schoevers, R.A., Turner, E.H., Reporting bias in clinical trials investigating the efficacy of second-generation antidepressants in the treatment of anxiety disorders: a report of 2 meta-analyses. JAMA Psychiatry 72 (2015), 500–510.
35. Rynn, M., Russell, J., Erickson, J., Detke, M.J., Ball, S., Dinkel, J., Rickels, K., Raskin, J., Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress. Anxiety 25 (2008), 182–189.
36. Saini, P., Loke, Y.K., Gamble, C., Altman, D.G., Williamson, P.R., Kirkham, J.J., Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. BMJ, 349, 2014, g6501.
37. Schroll, J.B., Maund, E., Gøtzsche, P.C., Challenges in coding adverse events in clinical trials: a systematic review. PLoS One, 7, 2012, e41174.
38. Sharma, T., Guski, L.S., Freund, N., Gøtzsche, P.C., Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ, 352, 2016, i65.
39. Sheehan, D.V., Burnham, D.B., Iyengar, M.K., Perera, P., Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J. Clin. Psychiatry 66 (2005), 34–40.
40. Soomro, G.M., Altman, D.G., Rajagopal, S., Oakley Browne, M., Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst. Rev., 2008, 1 CD001765.
41. Stein, D.J., Ipser, J.C., Seedat, S., Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst. Rev., 2006, 1 CD002795.
42. Stone, M., Laughren, T.P., Jones, M.L., Levenson, M., Holland, P.C., Hughes, A., Hammad, T.A., Temple, R., Rochester, G., Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ, 339, 2009, b2880.
43. Tang, E., Ravaud, P., Riveros, C., Perrodeau, E., Dechartres, A., Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles. BMC Med., 13, 2015, 189.
44. Turner, E.H., A taxpayer-funded clinical trials registry and results database. PLoS Med., 1, 2004, e60.
45. Turner, E.H., Knoepflmacher, D., Shapley, L., Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. PLoS Med, 9, 2012, e1001189.
46. Turner, E.H., Matthews, A.M., Linardatos, E., Tell, R.A., Rosenthal, R., Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med. 358 (2008), 252–260.
47. Van Ameringen, M.A., Lane, R.M., Walker, J.R., Bowen, R.C., Chokka, P.R., Goldner, E.M., Johnston, D.G., Lavallee, Y.J., et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am. J. Psychiatry 158 (2001), 275–281.
48. Vartiainen, H., Leinonen, E., Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. Eur. Neuropsychopharmacol. 4 (1994), 145–150.
49. Westenberg, H.G.M., Stein, D.J., Yang, H., Li, D., Barbato, L.M., A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J. Clin. Psychopharmacol. 24 (2004), 49–55.
50. Wieseler, B., Wolfram, N., McGauran, N., Kerekes, M.F., Vervölgyi, V., Kohlepp, P., Kamphuis, M., Grouven, U., Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. PLoS Med., 10, 2013, e1001526.